Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Journal of Clinical Oncology · 01.09.2025 · 43 (25) · 2772-2781
DOI: 10.1200/jco-25-00856 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.09.2025. Verfasst von Monzr M Al Malki und 32 weiteren Autor:innen. Beteiligte Einrichtung: City of Hope National Medical Center, Duarte, CA. Hauptthemen laut MEDLINE: Graft vs Host Disease, Cyclophosphamide, Peripheral Blood Stem Cell Transplantation, Unrelated Donors. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
PURPOSE Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for advanced hematologic malignancies. HSCT using human leukocyte antigen (HLA)-mismatched donors is historically associated with inferior survival. Patients from underrepresented racial and ethnic groups more frequently rely on HLA-mismatched donors. We hypothesized that post-transplant cyclophosphamide (PTCy) based graft versus host disease (GVHD) prophylaxis would improve outcomes for HSCT recipients using peripheral blood stem cells (PBSCs) from HLA-mismatched unrelated donors (MMUDs) by reducing the risk of GVHD. METHODS This phase II, nonrandomized, multicenter trial assessed PBSCs in the setting of a GVHD prophylaxis regimen of cyclophosphamide, tacrolimus, and mycophenolate mofetil in two adult strata: myeloablative conditioning (MAC) and reduced-intensity or nonmyeloablative (RIC/NMA) conditioning before HSCT from a MMUD. The primary objective was to estimate 1 year overall survival (OS) for each stratum. Key secondary end points included incidences of acute and chronic GVHD. RESULTS A total of 145 patients enrolled, with 59% self-identifying within an underrepresented group. The 1 year OS was 83.8% (95% CI, 73.1% to 90.4%) for MAC and 78.6% (95% CI, 67% to 86.5%) for RIC/NMA. Incidences of grades III to IV acute GVHD at 6 months were 8% (95% CI, 3.2 to 15.6) for MAC and 10% (95% CI, 4.4 to 18.4) for RIC/NMA. Moderate/severe chronic GVHD at 1 year was 10.3% (95% CI, 4.4 to 18.9) for MAC and 8.6% (95% CI, 3.5 to 16.6) for RIC/NMA. 32% of patients whose donors matched at fewer than seven of eight HLA alleles had similar OS compared with those with donor matched at seven of eight alleles. CONCLUSION PTCy-based GVHD prophylaxis after MMUD HSCT with PBSC grafts results in favorable 1 year OS. Using MMUDs expands donor availability to all patients regardless of ancestry (ACCESS; ClinicalTrials.gov identifier: NCT04904588 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- City of Hope National Medical Center, Duarte, CA.
- CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN.
- Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, WI.
- CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI.
- Health Sector & College of Medicine, Qatar University, Doha, Qatar.
- Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
ORCID-Profile: Monzr M Al Malki, Brent Logan, Jeffery J Auletta, Stephen R Spellman, Medhat Askar, Rachel Cusatis, Brian C Shaffer, Dipenkumar Modi, Farhad Khimani, Mehdi Hamadani, Abeer Madbouly, Martin Maiers, Stephanie Fingerson, Karen Ballen, Alison Loren, Karilyn Larkin, Muna Qayed, Sung Won Choi, Larisa Broglie, Bronwen E Shaw, Steven Michael Devine, Antonio Martin Jimenez Jimenez
Förderung
- NIEHS NIH HHS
- NIAID NIH HHS
- NHLBI NIH HHS
- NCI NIH HHS
Zitieren
APA
Al Malki, M. M., Bo-Subait, S., Logan, B., Olson, J., Kou, J., Smith, S., Leckrone, E., Wu, J., Stefanski, H. E., Auletta, J. J., Spellman, S. R., Malmberg, C., Askar, M., Cusatis, R., Shaffer, B. C., Modi, D., Khimani, F., Gooptu, M., Hamadani, M., …, & Jimenez Jimenez, A. M. (2025). Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation. Journal of Clinical Oncology, 43(25), 2772-2781. https://doi.org/10.1200/jco-25-00856
Vancouver
Al Malki MM, Bo-Subait S, Logan B, Olson J, Kou J, Smith S, et al. Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation. Journal of Clinical Oncology. 2025;43(25):2772-2781. doi:10.1200/jco-25-00856
BibTeX
@article{AlMalki2025,
author = {Al Malki, Monzr M and Bo-Subait, Stephanie and Logan, Brent and Olson, Janelle and Kou, Jianqun and Smith, Sarah and Leckrone, Erin and Wu, Juan and Stefanski, Heather E and Auletta, Jeffery J and Spellman, Stephen R and Malmberg, Craig and Askar, Medhat and Cusatis, Rachel and Shaffer, Brian C and Modi, Dipenkumar and Khimani, Farhad and Gooptu, Mahasweta and Hamadani, Mehdi and Madbouly, Abeer and Maiers, Martin and Fingerson, Stephanie and Cook, Rachel and Ballen, Karen and Loren, Alison and Larkin, Karilyn and Arai, Sally and Qayed, Muna and Choi, Sung Won and Broglie, Larisa and Shaw, Bronwen E and Devine, Steven Michael and Jimenez Jimenez, Antonio Martin},
title = {Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {25},
pages = {2772--2781},
doi = {10.1200/jco-25-00856}
}
EUVIMED